Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Leukemia

  Free Subscription


Articles published in Int J Hematol

Retrieve available abstracts of 139 articles:
HTML format
Text format



Single Articles


    March 2019
  1. FUJINO H, Ishida H, Iguchi A, Onuma M, et al
    High rates of ovarian function preservation after hematopoietic cell transplantation with melphalan-based reduced intensity conditioning for pediatric acute leukemia: an analysis from the Japan Association of Childhood Leukemia Study (JACLS).
    Int J Hematol. 2019 Mar 12. pii: 10.1007/s12185-019-02627.
    PubMed     Text format     Abstract available


  2. ARAI N, Homma M, Abe M, Baba Y, et al
    Impact of CD123 expression, analyzed by immunohistochemistry, on clinical outcomes in patients with acute myeloid leukemia.
    Int J Hematol. 2019 Mar 7. pii: 10.1007/s12185-019-02616.
    PubMed     Text format     Abstract available


  3. SASAKI K, Kantarjian HM, O'Brien S, Ravandi F, et al
    Incidence of second malignancies in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors.
    Int J Hematol. 2019 Mar 4. pii: 10.1007/s12185-019-02620.
    PubMed     Text format     Abstract available


  4. TOBINAI K, Uchida T, Fukuhara N, Nishikawa T, et al
    Ibrutinib in Japanese patients with relapsed/refractory B-cell malignancies: final analysis of phase I study.
    Int J Hematol. 2019;109:366-368.
    PubMed     Text format    


    February 2019
  5. ARAI K, Yoshifuji K, Motomura Y, Sonokawa S, et al
    Dasatinib for chronic myelogenous leukemia improves skin symptoms of systemic sclerosis.
    Int J Hematol. 2019 Feb 20. pii: 10.1007/s12185-019-02618.
    PubMed     Text format     Abstract available


  6. KIZAKI M, Takahashi N, Iriyama N, Okamoto S, et al
    Efficacy and safety of tyrosine kinase inhibitors for newly diagnosed chronic-phase chronic myeloid leukemia over a 5-year period: results from the Japanese registry obtained by the New TARGET system.
    Int J Hematol. 2019 Feb 14. pii: 10.1007/s12185-019-02613.
    PubMed     Text format     Abstract available


  7. HATSUMI N, Miyawaki S, Yamauchi T, Takeshita A, et al
    Phase II study of FLAGM (fludarabine + high-dose cytarabine + granulocyte colony-stimulating factor + mitoxantrone) for relapsed or refractory acute myeloid leukemia.
    Int J Hematol. 2019 Feb 6. pii: 10.1007/s12185-019-02606.
    PubMed     Text format     Abstract available


    January 2019
  8. YAMASHITA Y, Nishikawa A, Iwahashi Y, Fujimoto M, et al
    Identification of a novel CCDC22 mutation in a patient with severe Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis and aggressive natural killer cell leukemia.
    Int J Hematol. 2019 Jan 31. pii: 10.1007/s12185-019-02595.
    PubMed     Text format     Abstract available


  9. TSUKASAKI K, Fukushima T
    JSH Practical Guidelines for Hematological Malignancies, 2018: II. Lymphoma-8. Adult T-cell leukemia-lymphoma.
    Int J Hematol. 2019 Jan 30. pii: 10.1007/s12185-018-02588.
    PubMed     Text format    


  10. USAMI I, Imamura T, Takahashi Y, Suenobu SI, et al
    Discontinuation of L-asparaginase and poor response to prednisolone are associated with poor outcome of ETV6-RUNX1-positive pediatric B-cell precursor acute lymphoblastic leukemia.
    Int J Hematol. 2019 Jan 28. pii: 10.1007/s12185-019-02599.
    PubMed     Text format     Abstract available


  11. KAWASAKI Y, Kimura SI, Nakano H, Mashima K, et al
    Comparison of neutropenia profiles in different treatment protocols for acute myeloid leukemia using the D-index.
    Int J Hematol. 2019 Jan 25. pii: 10.1007/s12185-019-02593.
    PubMed     Text format     Abstract available


  12. SAKURAI M, Kikuchi T, Karigane D, Kasahara H, et al
    Renal dysfunction and anemia associated with long-term imatinib treatment in patients with chronic myelogenous leukemia.
    Int J Hematol. 2019 Jan 24. pii: 10.1007/s12185-019-02596.
    PubMed     Text format     Abstract available


  13. TANIGUCHI H, Imaizumi Y, Takasaki Y, Nakashima J, et al
    Clinical features at transformation in adult T-cell leukemia-lymphoma with smoldering and chronic types.
    Int J Hematol. 2019 Jan 24. pii: 10.1007/s12185-019-02602.
    PubMed     Text format     Abstract available


  14. TANAKA Y, Takahashi Y, Tanaka R, Miyagi T, et al
    Association of high levels of plasma OX40 with acute adult T-cell leukemia.
    Int J Hematol. 2019 Jan 16. pii: 10.1007/s12185-018-02580.
    PubMed     Text format     Abstract available


  15. BRUNETTI L, Gundry MC, Goodell MA
    New insights into the biology of acute myeloid leukemia with mutated NPM1.
    Int J Hematol. 2019 Jan 10. pii: 10.1007/s12185-018-02578.
    PubMed     Text format     Abstract available


    December 2018
  16. DOTSON J, Elhamdani A, Petryna E, Jamil MO, et al
    Neutropenic enterocolitis in patients with FLT3 mutated acute myeloid leukemia undergoing induction chemotherapy with midostaurin.
    Int J Hematol. 2018 Dec 3. pii: 10.1007/s12185-018-2558.
    PubMed     Text format     Abstract available


  17. TACHIBANA T, Koyama S, Andou T, Ishiyama Y, et al
    Salvage and bridging to allogeneic hematopoietic cell transplantation with ponatinib in patients with relapsed or refractory Philadelphia chromosome-positive leukemia.
    Int J Hematol. 2018 Dec 3. pii: 10.1007/s12185-018-02571.
    PubMed     Text format     Abstract available


  18. STANO KOZUBIK K, Radova L, Pesova M, Reblova K, et al
    C-terminal RUNX1 mutation in familial platelet disorder with predisposition to myeloid malignancies.
    Int J Hematol. 2018;108:652-657.
    PubMed     Text format     Abstract available


    November 2018
  19. UEDA T, Maeda T, Kusakabe S, Fujita J, et al
    Addition of melphalan to fludarabine/busulfan (FLU/BU4/MEL) provides survival benefit for patients with myeloid malignancy following allogeneic bone-marrow transplantation/peripheral blood stem-cell transplantation.
    Int J Hematol. 2018 Nov 17. pii: 10.1007/s12185-018-2562.
    PubMed     Text format     Abstract available


  20. WOLTERS R, Curry CV
    Conspicuous activated lymphocytic proliferation associated with cytokine-release syndrome after CAR T-cell therapy.
    Int J Hematol. 2018;108:461-462.
    PubMed     Text format    


  21. DOTSON JL, Jamil MO
    Successful treatment of cytarabine-related neurotoxicity with corticosteroids, a case series.
    Int J Hematol. 2018;108:554-557.
    PubMed     Text format     Abstract available


  22. KUAN JW, Su AT, Leong CF, Osato M, et al
    Systematic review of pre-clinical chronic myeloid leukaemia.
    Int J Hematol. 2018;108:465-484.
    PubMed     Text format     Abstract available


  23. OYA S, Muta T
    Breakthrough infection of Geotrichum capitatum during empirical caspofungin therapy after umbilical cord blood transplantation.
    Int J Hematol. 2018;108:558-563.
    PubMed     Text format     Abstract available


    October 2018
  24. KAMACHI K, Shindo T, Miyahara M, Kitaura K, et al
    Epstein-Barr virus-related diffuse large B-cell lymphoma in mogamulizumab-treated adult T-cell leukemia with incomplete T-cell reconstitution.
    Int J Hematol. 2018 Oct 27. pii: 10.1007/s12185-018-2552.
    PubMed     Text format     Abstract available


  25. KIZAKI M
    Molecular pathogenesis of leukemia and leukemic stem cells (LSCs).
    Int J Hematol. 2018 Oct 23. pii: 10.1007/s12185-018-2550.
    PubMed     Text format    


  26. HARADA K, Sekiya N, Ikegawa S, Sasaki S, et al
    Cytomegalovirus meningitis in a patient with relapsed acute myeloid leukemia.
    Int J Hematol. 2018 Oct 5. pii: 10.1007/s12185-018-2544.
    PubMed     Text format     Abstract available


  27. TAGA T, Imamura T, Nakashima K, Maeda N, et al
    Clinical characteristics of pediatric patients with myeloid sarcoma without bone marrow involvement in Japan.
    Int J Hematol. 2018;108:438-442.
    PubMed     Text format     Abstract available


    September 2018
  28. AZEVEDO PORTILHO N, Kobayashi M, Yoshimoto M
    What do the lineage tracing studies tell us? Consideration for hematopoietic stem cell origin, dynamics, and leukemia-initiating cells.
    Int J Hematol. 2018 Sep 27. pii: 10.1007/s12185-018-2537.
    PubMed     Text format     Abstract available


  29. RAKSZAWSKI K, Miki K, Claxton D, Wagner H, et al
    Clofarabine followed by haploidentical stem cell transplant using fludarabine, busulfan, and total-body irradiation with post-transplant cyclophosphamide in non-remission AML.
    Int J Hematol. 2018;108:348-350.
    PubMed     Text format     Abstract available


    August 2018
  30. MINAMI Y
    Guest editorial: chronic myeloid leukemia.
    Int J Hematol. 2018 Aug 28. pii: 10.1007/s12185-018-2521.
    PubMed     Text format    


  31. INOUE A, Kobayashi CI, Shinohara H, Miyamoto K, et al
    Chronic myeloid leukemia stem cells and molecular target therapies for overcoming resistance and disease persistence.
    Int J Hematol. 2018 Aug 28. pii: 10.1007/s12185-018-2519.
    PubMed     Text format     Abstract available


  32. WATANABE N, Takaku T, Takeda K, Shirane S, et al
    Dasatinib-induced anti-leukemia cellular immunity through a novel subset of CD57 positive helper/cytotoxic CD4 T cells in chronic myelogenous leukemia patients.
    Int J Hematol. 2018 Aug 27. pii: 10.1007/s12185-018-2517.
    PubMed     Text format     Abstract available


  33. TAN TK, Zhang C, Sanda T
    Oncogenic transcriptional program driven by TAL1 in T-cell acute lymphoblastic leukemia.
    Int J Hematol. 2018 Aug 25. pii: 10.1007/s12185-018-2518.
    PubMed     Text format     Abstract available


  34. KANAYAMA T, Imamura T, Kawabe Y, Osone S, et al
    KMT2A-rearranged infantile acute myeloid leukemia masquerading as juvenile myelomonocytic leukemia.
    Int J Hematol. 2018 Aug 24. pii: 10.1007/s12185-018-2522.
    PubMed     Text format     Abstract available


  35. SATO K, Sakai H, Saiki Y, Uchida A, et al
    Correction to: Cell dynamics during differentiation therapy with all-trans retinoic acid in acute promyelocytic leukemia.
    Int J Hematol. 2018 Aug 12. pii: 10.1007/s12185-018-2515.
    PubMed     Text format     Abstract available


  36. CHIBA A, Toya T, Mizuno H, Tokushige J, et al
    Chronic myelogenous leukemia presenting with central nervous system infiltration, successfully treated with central nervous system-directed chemotherapy followed by allogeneic stem cell transplantation.
    Int J Hematol. 2018 Aug 4. pii: 10.1007/s12185-018-2511.
    PubMed     Text format     Abstract available


  37. EVERS D, Bar BMAM, Gotthardt M, van der Velden WJFM, et al
    Activity of decitabine in pericardial myeloid sarcoma.
    Int J Hematol. 2018;108:121-122.
    PubMed     Text format    


    July 2018
  38. ITAMURA H, Ide M, Sato A, Sueoka-Aragane N, et al
    Identification of the BRAF V600E mutation in Japanese patients with hairy cell leukemia and related diseases using a quenching probe method.
    Int J Hematol. 2018 Jul 24. pii: 10.1007/s12185-018-2506.
    PubMed     Text format     Abstract available


  39. NAKASHIMA J, Imaizumi Y, Taniguchi H, Ando K, et al
    Clinical factors to predict outcome following mogamulizumab in adult T-cell leukemia-lymphoma.
    Int J Hematol. 2018 Jul 21. pii: 10.1007/s12185-018-2509.
    PubMed     Text format     Abstract available


  40. KURATA K, Nishimura S, Ichikawa H, Sakai R, et al
    Invasive Scopulariopsis alboflavescens infection in patient with acute myeloid leukemia.
    Int J Hematol. 2018 Jul 9. pii: 10.1007/s12185-018-2496.
    PubMed     Text format     Abstract available


    June 2018
  41. TAKEI H, Kobayashi SS
    Targeting transcription factors in acute myeloid leukemia.
    Int J Hematol. 2018 Jun 28. pii: 10.1007/s12185-018-2488.
    PubMed     Text format     Abstract available


  42. HASSAN IB, Kristensen J, Al Qawasmeh K, Alam A, et al
    Re-induction chemotherapy using FLAG-mitoxantrone for adult patients with relapsed acute leukemia: a single-center experience from United Arab Emirates.
    Int J Hematol. 2018 Jun 27. pii: 10.1007/s12185-018-2478.
    PubMed     Text format     Abstract available


  43. ORAVCOVA I, Mikuskova E, Leitnerova M, Gyarfas J, et al
    A unique clinical presentation of de novo acute promyelocytic leukemia as a myeloid sarcoma of the breast.
    Int J Hematol. 2018 Jun 21. pii: 10.1007/s12185-018-2479.
    PubMed     Text format     Abstract available


  44. KAWAI H, Matsushita H, Aoyama Y, Matsui K, et al
    Correction to: Dysplastic features seen in a patient with acute myeloid leukemia harboring the KMT2A-TET1 fusion gene.
    Int J Hematol. 2018 Jun 12. pii: 10.1007/s12185-018-2476.
    PubMed     Text format     Abstract available


  45. WILKINSON AC, Yamazaki S
    The hematopoietic stem cell diet.
    Int J Hematol. 2018;107:634-641.
    PubMed     Text format     Abstract available


  46. HOSOI H, Mushino T, Nishikawa A, Hashimoto H, et al
    Severe graft-versus-host disease after allogeneic hematopoietic stem cell transplantation with residual mogamulizumab concentration.
    Int J Hematol. 2018;107:717-719.
    PubMed     Text format    


    May 2018
  47. SATO K, Sakai H, Saiki Y, Uchida A, et al
    Cell dynamics during differentiation therapy with all-trans retinoic acid in acute promyelocytic leukemia.
    Int J Hematol. 2018 May 29. pii: 10.1007/s12185-018-2472.
    PubMed     Text format     Abstract available


  48. TOMOYASU C, Imamura T, Tomii T, Yano M, et al
    Copy number abnormality of acute lymphoblastic leukemia cell lines based on their genetic subtypes.
    Int J Hematol. 2018 May 21. pii: 10.1007/s12185-018-2474.
    PubMed     Text format     Abstract available


  49. KAWAI H, Matsushita H, Aoyama Y, Matsui K, et al
    Dysplastic features seen in a patient with acute myeloid leukemia harboring the KTM2A-TET1 fusion gene.
    Int J Hematol. 2018 May 9. pii: 10.1007/s12185-018-2469.
    PubMed     Text format    


  50. GOTOH N, Saitoh T, Takahashi N, Kasamatsu T, et al
    Association between OGG1 S326C CC genotype and elevated relapse risk in acute myeloid leukemia.
    Int J Hematol. 2018 May 8. pii: 10.1007/s12185-018-2464.
    PubMed     Text format     Abstract available


  51. ISHIKAWA J, Matsumura I, Kawaguchi T, Kuroda J, et al
    Efficacy and safety of switching to nilotinib in patients with CML-CP in major molecular response to imatinib: results of a multicenter phase II trial (NILSw trial).
    Int J Hematol. 2018;107:535-540.
    PubMed     Text format     Abstract available


    April 2018
  52. NOGUCHI S, Nakaseko C, Nishiwaki K, Ogasawara H, et al
    Switching to nilotinib is associated with deeper molecular responses in chronic myeloid leukemia chronic phase with major molecular responses to imatinib: STAT1 trial in Japan.
    Int J Hematol. 2018 Apr 30. pii: 10.1007/s12185-018-2459.
    PubMed     Text format     Abstract available


  53. TORIYAMA E, Imaizumi Y, Taniguchi H, Taguchi J, et al
    EPOCH regimen as salvage therapy for adult T-cell leukemia-lymphoma.
    Int J Hematol. 2018 Apr 12. pii: 10.1007/s12185-018-2455.
    PubMed     Text format     Abstract available


    March 2018
  54. WATANABE J, Sato K, Osawa Y, Horiuchi T, et al
    CBL mutation and MEFV single-nucleotide variant are important genetic predictors of tumor reduction in glucocorticoid-treated patients with chronic myelomonocytic leukemia.
    Int J Hematol. 2018 Mar 29. pii: 10.1007/s12185-018-2436.
    PubMed     Text format     Abstract available


  55. TAKAHASHI H, Kajiwara R, Kato M, Hasegawa D, et al
    Treatment outcome of children with acute lymphoblastic leukemia: the Tokyo Children's Cancer Study Group (TCCSG) Study L04-16.
    Int J Hematol. 2018 Mar 27. pii: 10.1007/s12185-018-2440.
    PubMed     Text format     Abstract available


  56. IMAMURA T, Taga T, Takagi M, Kawasaki H, et al
    Nationwide survey of therapy-related leukemia in childhood in Japan.
    Int J Hematol. 2018 Mar 24. pii: 10.1007/s12185-018-2439.
    PubMed     Text format     Abstract available


  57. SANO H, Kobayashi R, Suzuki D, Hori D, et al
    Impact of the D-index deduced from duration and intensity of neutropenia following chemotherapy on the risk of invasive fungal infection in pediatric acute myeloid leukemia.
    Int J Hematol. 2018 Mar 21. pii: 10.1007/s12185-018-2433.
    PubMed     Text format     Abstract available


  58. SANO H, Mochizuki K, Kobayashi S, Ohara Y, et al
    T-cell-replete haploidentical stem cell transplantation using low-dose antithymocyte globulin in children with relapsed or refractory acute leukemia.
    Int J Hematol. 2018 Mar 5. pii: 10.1007/s12185-018-2423.
    PubMed     Text format     Abstract available


  59. MIYOSHI H, Ohshima K
    Epidemiology of malignant lymphoma and recent progress in research on adult T-cell leukemia/lymphoma in Japan.
    Int J Hematol. 2018 Mar 3. pii: 10.1007/s12185-018-2430.
    PubMed     Text format     Abstract available


  60. KAWAMOTO H, Masuda K, Nagano S, Maeda T, et al
    Cloning and expansion of antigen-specific T cells using iPS cell technology: development of "off-the-shelf" T cells for the use in allogeneic transfusion settings.
    Int J Hematol. 2018;107:271-277.
    PubMed     Text format     Abstract available


    February 2018
  61. SUEMATSU M, Imamura T, Chiyonobu T, Osone S, et al
    Lumbosacral polyradiculopathy after intrathecal chemotherapy in pediatric acute lymphoblastic leukemia.
    Int J Hematol. 2018 Feb 22. pii: 10.1007/s12185-018-2427.
    PubMed     Text format    


  62. NAQVI K, Cortes JE, Luthra R, O'Brien S, et al
    Characteristics and outcome of chronic myeloid leukemia patients with E255K/V BCR-ABL kinase domain mutations.
    Int J Hematol. 2018 Feb 20. pii: 10.1007/s12185-018-2422.
    PubMed     Text format     Abstract available


  63. SATO S, Itonaga H, Taguchi M, Sawayama Y, et al
    Clonal dynamics in a case of acute monoblastic leukemia that later developed myeloproliferative neoplasm.
    Int J Hematol. 2018 Feb 7. pii: 10.1007/s12185-018-2419.
    PubMed     Text format     Abstract available


  64. SCHROEDER T, Rautenberg C, Haas R, Germing U, et al
    Hypomethylating agents for treatment and prevention of relapse after allogeneic blood stem cell transplantation.
    Int J Hematol. 2018;107:138-150.
    PubMed     Text format     Abstract available


  65. KOIZUMI Y, Furuya D, Endo T, Asanuma K, et al
    Quantification of Wilms' tumor 1 mRNA by digital polymerase chain reaction.
    Int J Hematol. 2018;107:230-234.
    PubMed     Text format     Abstract available


    January 2018
  66. TAKAMI A
    Hematopoietic stem cell transplantation for acute myeloid leukemia.
    Int J Hematol. 2018 Jan 27. pii: 10.1007/s12185-018-2412.
    PubMed     Text format     Abstract available


  67. SHIMADA A, Iijima-Yamashita Y, Tawa A, Tomizawa D, et al
    Risk-stratified therapy for children with FLT3-ITD-positive acute myeloid leukemia: results from the JPLSG AML-05 study.
    Int J Hematol. 2018 Jan 12. pii: 10.1007/s12185-017-2395.
    PubMed     Text format     Abstract available


    December 2017
  68. ABE A, Yamamoto Y, Katsumi A, Okamoto A, et al
    Rearrangement of VPS13B, a causative gene of Cohen syndrome, in a case of RUNX1-RUNX1T1 leukemia with t(8;12;21).
    Int J Hematol. 2017 Dec 20. pii: 10.1007/s12185-017-2387.
    PubMed     Text format     Abstract available


  69. MIYAMOTO T, Nagafuji K, Fujisaki T, Uchida N, et al
    Prospective randomization of post-remission therapy comparing autologous peripheral blood stem cell transplantation versus high-dose cytarabine consolidation for acute myelogenous leukemia in first remission.
    Int J Hematol. 2017 Dec 14. pii: 10.1007/s12185-017-2389.
    PubMed     Text format     Abstract available


  70. SUZUKI D, Kobayashi R, Sano H, Hori D, et al
    Sarcopenia after induction therapy in childhood acute lymphoblastic leukemia: its clinical significance.
    Int J Hematol. 2017 Dec 12. pii: 10.1007/s12185-017-2388.
    PubMed     Text format     Abstract available


    November 2017
  71. FUJIMAKI K, Hattori Y, Nakajima H
    10-year complete remission in a Philadelphia chromosome-positive acute lymphoblastic leukemia patient using imatinib without high-intensity chemotherapy or allogeneic stem cell transplantation.
    Int J Hematol. 2017 Nov 29. pii: 10.1007/s12185-017-2382.
    PubMed     Text format     Abstract available


  72. KIKUCHI J, Kuroda Y, Koyama D, Furukawa Y, et al
    Cell adhesion-induced phosphorylation and inactivation of EZH2 confer drug resistance to acute myeloid leukemia cells.
    Int J Hematol. 2017 Nov 28. pii: 10.1007/s12185-017-2376.
    PubMed     Text format    


  73. FUJIWARA SI, Shirato Y, Ikeda T, Kawaguchi SI, et al
    Successful treatment of follicular lymphoma with second-generation tyrosine kinase inhibitors administered for coexisting chronic myeloid leukemia.
    Int J Hematol. 2017 Nov 28. pii: 10.1007/s12185-017-2378.
    PubMed     Text format     Abstract available


  74. YAMAMOTO M, Hori T, Igarashi K, Iesato K, et al
    Non-alcoholic steatohepatitis induced by induction chemotherapy for pediatric acute lymphoblastic leukemia.
    Int J Hematol. 2017 Nov 27. pii: 10.1007/s12185-017-2377.
    PubMed     Text format    


  75. UEMURA S, Nishimura N, Hasegawa D, Shono A, et al
    ETV6-ABL1 fusion combined with monosomy 7 in childhood B-precursor acute lymphoblastic leukemia.
    Int J Hematol. 2017 Nov 24. pii: 10.1007/s12185-017-2371.
    PubMed     Text format     Abstract available


    October 2017
  76. COOK LB, Rowan AG, Demontis MA, Sagawe S, et al
    Long-term clinical remission maintained after cessation of zidovudine and interferon-alpha therapy in chronic adult T-cell leukemia/lymphoma.
    Int J Hematol. 2017 Oct 31. doi: 10.1007/s12185-017-2361.
    PubMed     Text format     Abstract available


  77. NAKAMAE H, Fukuda T, Nakaseko C, Kanda Y, et al
    Nilotinib vs. imatinib in Japanese patients with newly diagnosed chronic myeloid leukemia in chronic phase: long-term follow-up of the Japanese subgroup of the randomized ENESTnd trial.
    Int J Hematol. 2017 Oct 26. doi: 10.1007/s12185-017-2353.
    PubMed     Text format     Abstract available


  78. TAKEUCHI J, Kusumoto S, Akiyama H, Kanda Y, et al
    JSH guideline for tumors of hematopoietic and lymphoid tissues-leukemia: 3. Acute lymphoblastic leukemia/lymphoblastic lymphoma (ALL/LBL).
    Int J Hematol. 2017 Oct 24. doi: 10.1007/s12185-017-2350.
    PubMed     Text format    


  79. HONG CR, Kang HJ, Park KD, Shin HY, et al
    High-dose chemotherapy and autologous peripheral blood stem cell transplantation with BCVAC regimen followed by maintenance chemotherapy for children with very high risk acute lymphoblastic leukemia.
    Int J Hematol. 2017 Oct 20. doi: 10.1007/s12185-017-2355.
    PubMed     Text format     Abstract available


  80. KOZAKAI T, Takahashi M, Higuchi M, Hara T, et al
    MAGI-1 expression is decreased in several types of human T-cell leukemia cell lines, including adult T-cell leukemia.
    Int J Hematol. 2017 Oct 17. doi: 10.1007/s12185-017-2359.
    PubMed     Text format     Abstract available


  81. KOBAYASHI N, Shimizu H, Hirato J, Handa H, et al
    Collision of metastatic malignant melanoma and acute myelogenous leukemia in the bone marrow.
    Int J Hematol. 2017 Oct 17. doi: 10.1007/s12185-017-2356.
    PubMed     Text format    


  82. OKADA Y, Sato K, Kobayashi S, Nagao S, et al
    Sudden blast phase in chronic myeloid leukemia developed during nilotinib therapy after major molecular response was achieved.
    Int J Hematol. 2017 Oct 14. doi: 10.1007/s12185-017-2354.
    PubMed     Text format     Abstract available


  83. ISHIDA T, Akagawa N, Miyata T, Tominaga N, et al
    Dasatinib-associated reversible demyelinating peripheral polyneuropathy in a case of chronic myeloid leukemia.
    Int J Hematol. 2017 Oct 13. doi: 10.1007/s12185-017-2339.
    PubMed     Text format     Abstract available


  84. WANG Y, Xing Y, Chen L, Meng T, et al
    Fluconazole versus mould-active triazoles for primary antifungal prophylaxis in adult patients with acute lymphoblastic leukemia: clinical outcome and cost-effectiveness analysis.
    Int J Hematol. 2017 Oct 13. doi: 10.1007/s12185-017-2342.
    PubMed     Text format     Abstract available


  85. USUI N
    Correction to: JSH guideline for tumors of hematopoietic and lymphoid tissues-lukemia: 4. Chronic myelogenous leukemia (CML)/myeloproliferative neoplasms (MPN).
    Int J Hematol. 2017 Oct 12. doi: 10.1007/s12185-017-2351.
    PubMed     Text format     Abstract available


  86. KUWATSUKA Y, Tomizawa D, Kihara R, Nagata Y, et al
    Prognostic value of genetic mutations in adolescent and young adults with acute myeloid leukemia.
    Int J Hematol. 2017 Oct 12. doi: 10.1007/s12185-017-2340.
    PubMed     Text format     Abstract available


    September 2017
  87. USUI N
    JSH guideline for tumors of hematopoietic and lymphoid tissues-lukemia: 4. Chronic myelogenous leukemia (CML)/myeloproliferative neoplasms (MPN).
    Int J Hematol. 2017 Sep 21. doi: 10.1007/s12185-017-2330.
    PubMed     Text format    


  88. TAKAHASHI N, Tauchi T, Kitamura K, Miyamura K, et al
    Deeper molecular response is a predictive factor for treatment-free remission after imatinib discontinuation in patients with chronic phase chronic myeloid leukemia: the JALSG-STIM213 study.
    Int J Hematol. 2017 Sep 19. doi: 10.1007/s12185-017-2334.
    PubMed     Text format     Abstract available


  89. KOBAYASHI Y, Munakata W, Ogura M, Uchida T, et al
    Phase I study of panobinostat and 5-azacitidine in Japanese patients with myelodysplastic syndrome or chronic myelomonocytic leukemia.
    Int J Hematol. 2017 Sep 13. doi: 10.1007/s12185-017-2327.
    PubMed     Text format     Abstract available


  90. DELIA D, Mizutani S
    The DNA damage response pathway in normal hematopoiesis and malignancies.
    Int J Hematol. 2017;106:328-334.
    PubMed     Text format     Abstract available


    August 2017
  91. ASOU N, Fujita H, Shinagawa K
    JSH guideline for tumors of hematopoietic and lymphoid tissues: leukemia: 2. Acute promyelocytic leukemia (APL).
    Int J Hematol. 2017 Aug 30. doi: 10.1007/s12185-017-2318.
    PubMed     Text format    


  92. KOTAKI R, Higuchi H, Ogiya D, Katahira Y, et al
    Imbalanced expression of polycistronic miRNA in acute myeloid leukemia.
    Int J Hematol. 2017 Aug 22. doi: 10.1007/s12185-017-2314.
    PubMed     Text format     Abstract available


  93. HAN DM, Zheng XL, Ding L, Yan HM, et al
    Risk factors in patients undergoing haploidentical hematopoietic stem cell transplantation for high-risk childhood acute leukemia.
    Int J Hematol. 2017 Aug 20. doi: 10.1007/s12185-017-2317.
    PubMed     Text format     Abstract available


  94. HARA R, Onizuka M, Matsusita E, Kikkawa E, et al
    NKG2D gene polymorphisms are associated with disease control of chronic myeloid leukemia by dasatinib.
    Int J Hematol. 2017 Aug 9. doi: 10.1007/s12185-017-2294.
    PubMed     Text format     Abstract available


  95. MIYAWAKI S
    JSH guideline for tumors of hematopoietic and lymphoid tissues: leukemia 1. Acute myeloid leukemia (AML).
    Int J Hematol. 2017 Aug 7. doi: 10.1007/s12185-017-2303.
    PubMed     Text format    


  96. FEURSTEIN S, Godley LA
    Germline ETV6 mutations and predisposition to hematological malignancies.
    Int J Hematol. 2017;106:189-195.
    PubMed     Text format     Abstract available


  97. CHEAH JJC, Hahn CN, Hiwase DK, Scott HS, et al
    Myeloid neoplasms with germline DDX41 mutation.
    Int J Hematol. 2017;106:163-174.
    PubMed     Text format     Abstract available


  98. HAYASHI Y, Harada Y, Huang G, Harada H, et al
    Myeloid neoplasms with germ line RUNX1 mutation.
    Int J Hematol. 2017;106:183-188.
    PubMed     Text format     Abstract available


  99. HUA Y, Wang C, Jiang H, Wang Y, et al
    Iron overload may promote alteration of NK cells and hematopoietic stem/progenitor cells by JNK and P38 pathway in myelodysplastic syndromes.
    Int J Hematol. 2017;106:248-257.
    PubMed     Text format     Abstract available


    July 2017
  100. GEYER JT, Mathew S
    Myelomonocytic leukemia with intracytoplasmic crystalline inclusions, double minute chromosomes and MYC amplification.
    Int J Hematol. 2017 Jul 28. doi: 10.1007/s12185-017-2299.
    PubMed     Text format    


  101. DI IANNI M, Olioso P, Giancola R, Santarone S, et al
    Treg-protected donor lymphocyte infusions: a new tool to address the graft-versus-leukemia effect in the absence of graft-versus-host disease in patients relapsed after HSCT.
    Int J Hematol. 2017 Jul 18. doi: 10.1007/s12185-017-2292.
    PubMed     Text format     Abstract available


  102. REA D, Cayuela JM
    Treatment-free remission in patients with chronic myeloid leukemia.
    Int J Hematol. 2017 Jul 8. doi: 10.1007/s12185-017-2295.
    PubMed     Text format     Abstract available


  103. HIRANO M, Ohno N, Tanosaki R, Mochizuki M, et al
    Adult T-cell leukemia cell-induced uveitis: rapid increase in adult T-cell leukemia cells disrupts the blood-ocular barrier.
    Int J Hematol. 2017 Jul 4. doi: 10.1007/s12185-017-2293.
    PubMed     Text format     Abstract available


  104. MIYAZAKI Y
    JSH Guideline for Tumors of Hematopoietic and Lymphoid Tissues: Leukemia: 6. Myelodysplastic syndromes (MDS).
    Int J Hematol. 2017 Jul 4. doi: 10.1007/s12185-017-2272.
    PubMed     Text format    


  105. UEMURA S, Tamura A, Saito A, Hasegawa D, et al
    Reemergence of translocation t(11;19)(q23;p13.1) in the absence of clinically overt leukemia.
    Int J Hematol. 2017 Jul 1. doi: 10.1007/s12185-017-2289.
    PubMed     Text format     Abstract available


  106. KUNIMOTO H, Nakajima H
    Epigenetic dysregulation of hematopoietic stem cells and preleukemic state.
    Int J Hematol. 2017;106:34-44.
    PubMed     Text format     Abstract available


  107. KARIGANE D, Takubo K
    Metabolic regulation of hematopoietic and leukemic stem/progenitor cells under homeostatic and stress conditions.
    Int J Hematol. 2017;106:18-26.
    PubMed     Text format     Abstract available


  108. MATSUO H, Shiga S, Imai T, Kamikubo Y, et al
    Purification of leukemic blast cells from blood smears using laser microdissection.
    Int J Hematol. 2017;106:55-59.
    PubMed     Text format     Abstract available


    June 2017
  109. TANG S, Shen H, Mao X, Dai H, et al
    FLT3-ITD with DNMT3A R882 double mutation is a poor prognostic factor in Chinese patients with acute myeloid leukemia after chemotherapy or allogeneic hematopoietic stem cell transplantation.
    Int J Hematol. 2017 Jun 14. doi: 10.1007/s12185-017-2256.
    PubMed     Text format     Abstract available


  110. ISHITSUKA K, Yurimoto S, Kawamura K, Tsuji Y, et al
    Safety and efficacy of mogamulizumab in patients with adult T-cell leukemia-lymphoma in Japan: interim results of postmarketing all-case surveillance.
    Int J Hematol. 2017 Jun 9. doi: 10.1007/s12185-017-2270.
    PubMed     Text format     Abstract available


  111. ZHANG R, Chen J, Huang H, Ma J, et al
    Erratum to: Primary fungal prophylaxis in acute leukemia patients with different risk factors: retrospective analysis from the CAESAR study.
    Int J Hematol. 2017 Jun 2. doi: 10.1007/s12185-017-2269.
    PubMed     Text format    


  112. ITZYKSON R, Duchmann M, Lucas N, Solary E, et al
    CMML: Clinical and molecular aspects.
    Int J Hematol. 2017;105:711-719.
    PubMed     Text format     Abstract available


    May 2017
  113. TAMURA A, Uemura S, Saito A, Okubo S, et al
    Congenital immature pure erythroid leukemia with E-cadherin expression.
    Int J Hematol. 2017 May 18. doi: 10.1007/s12185-017-2248.
    PubMed     Text format     Abstract available


  114. MINAKATA D, Fujiwara SI, Ikeda T, Toda Y, et al
    Relationship between white blood cell count elevation and clinical response after G-CSF priming chemotherapy for acute myeloid leukemia.
    Int J Hematol. 2017 May 15. doi: 10.1007/s12185-017-2251.
    PubMed     Text format     Abstract available


  115. HANEKAMP D, Cloos J, Schuurhuis GJ
    Leukemic stem cells: identification and clinical application.
    Int J Hematol. 2017;105:549-557.
    PubMed     Text format     Abstract available


  116. TAKAGI M, Ishiwata Y, Aoki Y, Miyamoto S, et al
    HLA haploidentical hematopoietic cell transplantation using clofarabine and busulfan for refractory pediatric hematological malignancy.
    Int J Hematol. 2017;105:686-691.
    PubMed     Text format     Abstract available


  117. CAMACHO V, McClearn V, Patel S, Welner RS, et al
    Regulation of normal and leukemic stem cells through cytokine signaling and the microenvironment.
    Int J Hematol. 2017;105:566-577.
    PubMed     Text format     Abstract available


  118. IKEGAME K, Kaida K, Yoshihara S, Yoshihara K, et al
    Spousal hematopoietic stem cell transplantation.
    Int J Hematol. 2017;105:646-657.
    PubMed     Text format     Abstract available


  119. URESHINO H, Kizuka H, Kusaba K, Sano H, et al
    5q- syndrome-like features as the first manifestation of myelodysplastic syndrome in a patient with an unbalanced whole-arm translocation der(5;19)(p10;q10).
    Int J Hematol. 2017;105:692-696.
    PubMed     Text format     Abstract available


    April 2017
  120. TOJO A, Kyo T, Yamamoto K, Nakamae H, et al
    Ponatinib in Japanese patients with Philadelphia chromosome-positive leukemia, a phase 1/2 study.
    Int J Hematol. 2017 Apr 25. doi: 10.1007/s12185-017-2238.
    PubMed     Text format     Abstract available


  121. HATAKE K, Ogura M, Takada K, Taniwaki M, et al
    Ofatumumab combined with chlorambucil for previously untreated chronic lymphocytic leukemia: a phase I/II, open-label study in Japan.
    Int J Hematol. 2017 Apr 18. doi: 10.1007/s12185-017-2233.
    PubMed     Text format     Abstract available


  122. KE S, Li RC, Lu J, Meng FK, et al
    MicroRNA-192 regulates cell proliferation and cell cycle transition in acute myeloid leukemia via interaction with CCNT2.
    Int J Hematol. 2017 Apr 13. doi: 10.1007/s12185-017-2232.
    PubMed     Text format     Abstract available


  123. TAKAHASHI N, Nakaseko C, Kobayashi Y, Miyamura K, et al
    Long-term treatment with bosutinib in a phase 1/2 study in Japanese chronic myeloid leukemia patients resistant/intolerant to prior tyrosine kinase inhibitor treatment.
    Int J Hematol. 2017 Apr 13. doi: 10.1007/s12185-017-2239.
    PubMed     Text format     Abstract available


  124. IGUCHI A, Cho Y, Sugiyama M, Terashita Y, et al
    Bortezomib combined with standard induction chemotherapy in Japanese children with refractory acute lymphoblastic leukemia.
    Int J Hematol. 2017 Apr 11. doi: 10.1007/s12185-017-2235.
    PubMed     Text format     Abstract available


  125. ONG SY, Ho LP, Yeo PM, Ng HJ, et al
    Marked hypereosinophilia and rash as initial presentation of acute myeloid leukemia with t(8;21).
    Int J Hematol. 2017 Apr 7. doi: 10.1007/s12185-017-2230.
    PubMed     Text format    


  126. ZHANG R, Chen J, Huang H, Ma J, et al
    Primary fungal prophylaxis in acute leukemia patients with different risk factors: retrospective analysis from the CAESAR study.
    Int J Hematol. 2017 Apr 7. doi: 10.1007/s12185-017-2224.
    PubMed     Text format     Abstract available


  127. SUH KJ, Lee JY, Shin DY, Koh Y, et al
    Analysis of adverse events associated with dasatinib and nilotinib treatments in chronic-phase chronic myeloid leukemia patients outside clinical trials.
    Int J Hematol. 2017 Apr 4. doi: 10.1007/s12185-017-2225.
    PubMed     Text format     Abstract available


  128. YAGUCHI A, Ishibashi T, Terada K, Ueno-Yokohata H, et al
    EP300-ZNF384 fusion gene product up-regulates GATA3 gene expression and induces hematopoietic stem cell gene expression signature in B-cell precursor acute lymphoblastic leukemia cells.
    Int J Hematol. 2017 Apr 4. doi: 10.1007/s12185-017-2220.
    PubMed     Text format     Abstract available


  129. ASANO M, Umezu T, Katagiri S, Kobayashi C, et al
    Up-regulated exosomal miRNA-140-3p in CML patients with musculoskeletal pain associated with discontinuation of tyrosine kinase inhibitors.
    Int J Hematol. 2017;105:419-422.
    PubMed     Text format     Abstract available


    March 2017
  130. NAKAMAE H, Fujisawa S, Ogura M, Uchida T, et al
    Dasatinib versus imatinib in Japanese patients with newly diagnosed chronic phase chronic myeloid leukemia: a subanalysis of the DASISION 5-year final report.
    Int J Hematol. 2017 Mar 24. doi: 10.1007/s12185-017-2208.
    PubMed     Text format     Abstract available


  131. BARAKA A, Sherief LM, Kamal NM, Shorbagy SE, et al
    Detection of minimal residual disease in childhood B-acute lymphoblastic leukemia by 4-color flowcytometry.
    Int J Hematol. 2017 Mar 21. doi: 10.1007/s12185-017-2206.
    PubMed     Text format     Abstract available


  132. KATZ BZ, Herishanu Y
    Fragility of sub-cellular structures in chronic lymphocytic leukemia.
    Int J Hematol. 2017 Mar 21. doi: 10.1007/s12185-017-2218.
    PubMed     Text format    


  133. LOVATO S, Ayto R
    Haemolysis in female patient with chronic phase CML.
    Int J Hematol. 2017;105:233-234.
    PubMed     Text format    


  134. KANAMITSU K, Shimada A, Nishiuchi R, Shigemura T, et al
    Pediatric intestinal Behcet disease complicated by myeloid malignancies.
    Int J Hematol. 2017;105:377-382.
    PubMed     Text format     Abstract available


    January 2017
  135. WAISBREN J, Dinner S, Altman J, Frankfurt O, et al
    Disease characteristics and prognosis of myelodysplastic syndrome presenting with isolated thrombocytopenia.
    Int J Hematol. 2017;105:44-51.
    PubMed     Text format     Abstract available


    November 2016
  136. UEMURA M, Imataki O, Kawachi Y, Kawakami K, et al
    Charlson comorbidity index predicts poor outcome in CML patients treated with tyrosine kinase inhibitor.
    Int J Hematol. 2016;104:621-627.
    PubMed     Text format     Abstract available


  137. JUNG KS, Cho SH, Kim SJ, Ko YH, et al
    Clinical features and treatment outcome of Epstein-Barr virus-positive nodal T-cell lymphoma.
    Int J Hematol. 2016;104:591-595.
    PubMed     Text format     Abstract available


  138. RUBIO P, Campos B, Digiorge JA, Gallego MS, et al
    NPM1, FLT3 and CEBPA mutations in pediatric patients with AML from Argentina: incidence and prognostic value.
    Int J Hematol. 2016;104:582-590.
    PubMed     Text format     Abstract available


  139. MONIKA BELICKOVA M, Merkerova MD, Votavova H, Valka J, et al
    Up-regulation of ribosomal genes is associated with a poor response to azacitidine in myelodysplasia and related neoplasms.
    Int J Hematol. 2016;104:566-573.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: